The BlockDAG token holders are reassessing their options in the wake of the completed BlockDAG token phase, and this reassessment is having a strong influence onThe BlockDAG token holders are reassessing their options in the wake of the completed BlockDAG token phase, and this reassessment is having a strong influence on

BlockDag Holders Seek Alternative After Presale Concludes. Remittix Tops Rankings Globally

2026/02/10 13:06
5 min read

The BlockDAG token holders are reassessing their options in the wake of the completed BlockDAG token phase, and this reassessment is having a strong influence on the current behavior of the crypto market.

BlockDAG was created as a next-generation Layer 1 blockchain network with a proof-of-work and DAG data structure combination. This promising technology caught positive attention from various crypto news outlets as well as from investors who take an interest in blockchain technology.

BlockDag Holders Seek Alternative After Presale Concludes. Remittix Tops Rankings Globally

As that cycle closes, attention is shifting toward projects already operating in the real economy. This shift explains why Remittix is increasingly mentioned alongside BlockDAG in discussions around the best crypto to buy now. Investors are showing a clear preference for digital assets that pair strong technical foundations with immediate utility, especially as market sentiment becomes more selective.

BlockDAG’s Role and the Rotation of Capital

BlockDAG made its entry into the crypto world with an emphasis on decentralization, speed, and security. Combining Bitcoin-like security with DAG scalability, it aimed to solve many of the traditional blockchain congestion and efficiency problems. This has allowed the project to be among the most talked-about altcoins that are associated with Layer 1 innovation.

Once participation concluded, many BlockDAG holders began scanning the wider crypto market for projects with visible execution rather than future frameworks. This rotation is a familiar pattern in crypto cycles. When one opportunity closes, liquidity often moves toward platforms showing active deployment, clear roadmaps, and growing adoption.

Why Remittix Is Emerging as the Preferred Alternative

Remittix is increasingly viewed as that destination. The RTX token is priced at $0.123, and Remittix has raised over $29.1 million through private funding, reflecting strong demand from crypto investors focused on payments and financial access.

The most striking data point is supply pressure. More than 708 million of the fixed 750 million tokens are already secured, meaning over 97% of total tokens are gone. This level of allocation leaves a narrow window for remaining participants.

Urgency is accelerating quickly. Investors are openly racing to secure exposure as comparisons to early XRP adoption gain traction across social channels. That narrative is reinforced by a 300% bonus available via email, which has become a central driver of recent activity, with the team confirming the bonus will be extended following sustained participation.

Confirmed Product Delivery Changes the Conversation

Unlike many altcoins competing for attention, Remittix has already delivered a live product. The Remittix Wallet is fully launched on the Apple App Store, allowing users to store, send, and manage crypto assets today. This is not a beta release. It is a functional wallet operating as Phase 1 of a broader PayFi ecosystem.

A Google Play release is already in motion, expanding reach and supporting crypto adoption across mobile platforms. The wallet launch has shifted Remittix coverage from speculation to execution. It confirms that development milestones are being met on schedule, a key factor influencing current crypto analysis and investor confidence.

Platform Launch and the $30 Million Milestone

The next major catalyst is clearly defined. Remittix has confirmed that its full crypto-to-fiat PayFi platform will go live on 9 February 2026. On that date, users will gain access to the first complete release of the Remittix Platform, designed to bridge cryptocurrency with real-world finance.

This includes payment rails, conversion tools, and infrastructure aimed at everyday use rather than niche applications. Momentum is also building toward the $30 million mark. When reached, Remittix will reveal a major centralized exchange listing, while future listings on BitMart and LBank are already secured.

Remittix recently achieved a major credibility milestone after receiving full verification from CertiK. The project is also ranked as the #1 pre-launch token on CertiK, strengthening investor confidence and highlighting platform transparency.

Why Timing Is Now Critical

For BlockDAG holders seeking an alternative, Remittix presents a rare combination of tightening supply, active product deployment, and near-term milestones. The numbers underline the urgency. Over 97% of tokens are already secured, the 300% email bonus remains active, and the next funding milestone unlocks major exchange exposure.

Why Remittix Is Gaining Momentum

  • Live wallet on the App Store, with Google Play release underway
  • Crypto-to-fiat PayFi platform launching on 9 February 2026
  • Over $29.1 million raised through private funding
  • More than 708 million tokens already secured
  • Major CEX reveal scheduled at the $30 million milestone

As BlockDAG’s chapter closes, Remittix is rapidly becoming the focal point for investors repositioning within the crypto market. With supply nearly exhausted and key announcements ahead, the window to act at current levels is narrowing fast.

Discover the future of PayFi with Remittix by checking out their project here:

Website: remittix.io

Socials: https://linktr.ee/remittix

Comments
Market Opportunity
Talisman Logo
Talisman Price(SEEK)
$0.04907
$0.04907$0.04907
-5.14%
USD
Talisman (SEEK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26